- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Exenatide – March 2019
Exenatide: Injection 2 mg in 0.85 mL single dose autoinjector; Bydureon® BCise®
Last updated
19 July 2019